Aghlara-Fotovat, Samira http://orcid.org/0000-0002-1760-3786
Nash, Amanda http://orcid.org/0000-0002-7704-4912
Kim, Boram http://orcid.org/0000-0002-4758-4547
Krencik, Robert
Veiseh, Omid http://orcid.org/0000-0003-1153-8079
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK120459)
Cancer Prevention and Research Institute of Texas (RR160047)
Article History
Accepted: 10 June 2021
First Online: 26 June 2021
Declarations
:
: All the authors consent to participate.
: All authors consent to the publication of this manuscript.
: OV declares financial interests as a paid consultant and/or equity holder in Sigilon Therapeutics, Pana Biotherapeutics, Auregen BioTherapeutics, Avenge Bio, and Establishment Labs.